Harvard Bioscience, Inc.
HBIO
$0.3706
$0.01855.25%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -972.43% | 100.99% | -287.57% | -198.67% | -854.66% |
| Total Depreciation and Amortization | -7.07% | -0.96% | 2.02% | 4.65% | 3.49% |
| Total Amortization of Deferred Charges | 87.14% | 40.00% | 27.14% | 0.00% | 0.00% |
| Total Other Non-Cash Items | 1,792.36% | -76.55% | 849.07% | -36.69% | 265.18% |
| Change in Net Operating Assets | 105.62% | -124.82% | -85.29% | -1,801.20% | 231.79% |
| Cash from Operations | 112.83% | -59.91% | -119.31% | -123.82% | -22.57% |
| Capital Expenditure | 20.47% | 63.73% | -305.53% | -58.22% | -187.95% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -140.48% | 28.57% | -25.54% | 1,281.48% | -- |
| Cash from Investing | -203.56% | 56.08% | -177.06% | 173.28% | -178.13% |
| Total Debt Issued | -- | -100.00% | 225.00% | 205.00% | 66.67% |
| Total Debt Repaid | 71.62% | 69.23% | 73.33% | 17.57% | 18.84% |
| Issuance of Common Stock | -- | -21.84% | -- | -69.52% | -85.58% |
| Repurchase of Common Stock | -59.57% | 75.00% | -- | 95.93% | 69.87% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -14.12% | 67.03% | 176.51% | 107.45% | 63.53% |
| Foreign Exchange rate Adjustments | 324.50% | -98.36% | 290.72% | 123.53% | -304.05% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 5,235.71% | 56.39% | -48.72% | -138.69% | 96.11% |